GASTROPARESI: EPIDEMIOLOGIA E TERAPIE DI REAL-WORLD EVIDENCE. UNO STUDIO SU GASTROENTEROLOGY DAL GRUPPO DI CAMILLERI

Epidemiology, etiology and treatment of gastroparesis: real-world evidence from a large US national claims database Y. Ye et al. Background & Aims While gastroparesis carries a considerable healthcare and patient burden, associated epidemiological data are limited. To provide new real-world evidence for gastroparesis, we estimated disease prevalence, and investigated patient demographics and disease etiology in…

LE NUOVE TERAPIE BIOLOGICHE E CON “SMALL MOLECULES” PER LE IBD. UNA GRANDE REVISIONE DAL NEJM

Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease Daniel C. Baumgart et al. Crohn’s disease and ulcerative colitis, together referred to as inflammatory bowel disease (IBD), are chronic systemic inflammatory disorders.1 These conditions target primarily the gastrointestinal tract but can affect many organ systems through extraintestinal manifestations (e.g., peripheral and axial arthritis, episcleritis, primary…

COVID-19: ANCORA UNO STUDIO ” NON PEER-REVIEWED” RITIRATO DOPO 150.000 VISIONI. IL CASO IVERMECTIN SU “NATURE”

Flawed ivermectin preprint highlights challenges of COVID drug studies The study’s withdrawal from a preprint platform deals a blow to the anti-parasite drug’s chances as a COVID treatment, researchers say. Sara Reardon “Before its withdrawal, the paper was viewed more than 150,000 times, cited more than 30 times and included in a number of meta-analyses…

COVID-19: IVERMECTINA SOTTO STUDIO CON QUALCHE POLEMICA. UNA NOTA DALLA BIBLIOTECA DELLA ASSOCIAZIONE LIBERATI

Covid-19: ivermectina alla prova Pubblicato martedì 21 Settembre 2021 Sulla base delle prove attuali, non c’è sufficiente certezza sull’efficacia e la sicurezza dell’ivermectina per trattare o prevenire il covid-19. Questo in base a una revisione Cochrane di cui si è parlato molto nelle ultime settimane. L’ivermectina è un farmaco usato per trattare i parassiti, per esempio…